Designation recognizes ISP-002, an engineered B cell therapy designed for sustained enzyme delivery SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ — Immusoft

AN2 aims to advance oral treatment option for patients currently reliant on complex, off-label IV therapies Led by nontuberculous mycobacteria

Orphan Drug Designation for MPS II builds on Immusoft’s clinical progress in MPS I and supports expansion of its engineered

Advancing Phase 1 program in Chagas Disease; Phase 2 planning underway Clinical-stage M. abscessus program advancing through investigator-initiated trial (IIT)

AN2 awarded third year of funding from Gates Foundation MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 10, 2025-- AN2 Therapeutics, Inc. (Nasdaq:

MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 6, 2025-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing

The re-dose of ISP-001 has been well-tolerated, to date, and Immusoft continues to observe positive results SAN FRANCISCO, Oct. 7, 2025

Prospectively designed for scalability and re-dosability, Immusoft's engineered B cells represent the next generation of advanced therapeutics SAN FRANCISCO, Oct. 21, 2025 /PRNewswire/

Cash, cash equivalents, and investments of $71.2 million at June 30,2025 and cash runway anticipated to fund operations into 2028